Azacitidine plus pembrolizumab for Hodgkin lymphoma after relapse
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 2 study tests azacitidine together with pembrolizumab in people whose Hodgkin lymphoma has come back or did not respond (relapsed/refractory). It aims to see whether this combination can control cancer and improve outcomes, especially when standard high-dose chemotherapy is not an option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have relapsed or progressing Hodgkin lymphoma (HL), including cases outside the lymph nodes (extranodal sites), or you may qualify under other allowed cancer groups
- You are not a good candidate for high-dose conventional chemotherapy for HL, or your treating team says this fits your situation
- You’re 1 year or older, and your daily functioning is good enough for study treatment (ECOG ≤3 or for children, Lansky score ≥50)
- Your kidneys and liver blood tests are within allowed ranges for your age
- You can take the study medicines safely: no allergy to azacitidine or pembrolizumab
- If you can become pregnant or father a child, you must use effective birth control during treatment and for a set time after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two medicines—azacitidine and a PD-1 inhibitor—for people with Hodgkin lymphoma that has returned or not responded to previous treatment. The aim is to see if this combination can help control the disease.
This study tests a combination of the immunotherapy drug pembrolizumab with a chemotherapy regimen called GVD for patients whose Hodgkin's lymphoma has not responded or has returned after initial treatment. The goal is to see if this combination works better than standard approaches.
This trial studies whether adding atezolizumab to a chemotherapy-type treatment (the BEGEV regimen) can shrink Hodgkin lymphoma that has come back or did not respond. It may help people who have only had one prior whole-system (systemic) treatment and can still receive stem cell transplant (ASCT).
This Phase 2 trial tests whether pembrolizumab plus brentuximab works better than standard chemotherapy followed by an autologous stem cell transplant for people whose classic Hodgkin lymphoma has come back or did not respond. It may help by improving cancer control before and around stem cell transplant and by comparing outcomes between the two treatment approaches.
This study tests whether combining the immunotherapy drug pembrolizumab (Keytruda) with the chemotherapy bendamustine can help people with Hodgkin lymphoma whose cancer returned or did not respond to earlier treatment. The goal is to see if this two-drug combination works better than either drug alone.
This Phase 2 study tests whether pembrolizumab combined with salvage (second-line) chemotherapy can treat people whose classical Hodgkin lymphoma has either come back after initial treatment or did not respond to initial treatment. You may benefit if you have first-relapsed or refractory classical Hodgkin lymphoma and meet other study rules.
Hear when a new Hodgkin's Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.